Wechselwirkungen · Harvoni
Harvoni 33.75 mg/150 mg coated granules in sachet Harvoni 45 mg/200 mg coated granules in sachet · Abschnitt 4.5 · PDF-Seite 55
HOS-132363 · Präparat HOS-097208
GS-331007 ↔ Cmax 1.09 (0.99, 1.19) ↔ AUC 1.02 (0.97, 1.08) Elvitegravir/ cobicistat/ Interaction not studied. When given with elvitegravir/ cobicistat/ emtricitabine/ tenofovir Expected: emtricitabine/ tenofovir disoproxil fumarate, disoproxil fumarate ↔ Emtricitabine Harvoni is expected to increase the concentration of (150 mg/ 150 mg/ 200 mg/ ↑ Tenofovir tenofovir. 300 mg once daily)/ ledipasvir (90 mg once Observed: The safety of tenofovir disoproxil fumarate in the daily)c/ sofosbuvir (400 mg Elvitegravir setting of Harvoni and a pharmacokinetic enhancer once daily)c ↔ Cmax 0.88 (0.82, 0.95) (e.g. ritonavir or cobicistat) has not been ↔ AUC 1.02 (0.95, 1.09) established. ↑ Cmin 1.36 (1.23, 1.49) The combination should be used with caution with Cobicistat frequent renal monitoring, if other alternatives are ↔ Cmax 1.25 (1.18, 1.32) not available (see section 4.4). ↑ AUC 1.59 (1.49, 1.70) ↑ Cmin 4.25 (3.47, 5.22)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) cobicistat (HOS-088111) fumarate (HOS-108845) tenofovir disoproxil fumarate (HOS-110471) ritonavir (HOS-084521) elvitegravir (HOS-088110) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-11-10T14:39:00Z · SHA-256 5d503d87078c6a22bb188ba98b9837581fe648589d1f57d0325892e2bbaabbb1 · Passage c99f5ff5f6ea61a0be6ef5b33113519f442cd9ae9957dc1ab8f947ae1f49c1a1 · Zeichen 29093–30478 im Abschnitt